<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28789" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Scopolamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Riad</surname>
            <given-names>Marina</given-names>
          </name>
          <aff>Kettering Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hithe</surname>
            <given-names>Candice C.</given-names>
          </name>
          <aff>Grandview Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marina Riad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Candice Hithe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28789.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Scopolamine is a medication used to manage and treat postoperative nausea and vomiting (PONV) and motion sickness. It is in the anticholinergic class of drugs. This activity will highlight the indications, mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the care of patients with PONV and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of scopolamine.</p></list-item><list-item><p>Describe the potential adverse effects of scopolamine.</p></list-item><list-item><p>Explain the signs of scopolamine toxicity and its proper management.</p></list-item><list-item><p>Review team strategies for improving care coordination and communication to advance scopolamine therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28789">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28789.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Scopolamine is a medication used to manage and treat postoperative nausea and vomiting (PONV) and motion sickness. It is in the anticholinergic class of drugs.</p>
        <p>
<bold>FDA Labeled Indications</bold>
<xref ref-type="bibr" rid="article-28789.r1">[1]</xref>
<xref ref-type="bibr" rid="article-28789.r2">[2]</xref>
</p>
        <p>There are two FDA approved indications for the use of scopolamine:</p>
        <list list-type="bullet">
          <list-item>
            <p>Postoperative nausea and vomiting (PONV) associated with recovery from anesthesia, opiate analgesia, and surgery</p>
          </list-item>
          <list-item>
            <p>Nausea and vomiting associated with motion sickness&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Labeled Indications</bold>
<xref ref-type="bibr" rid="article-28789.r3">[3]</xref>
<xref ref-type="bibr" rid="article-28789.r4">[4]</xref>
<xref ref-type="bibr" rid="article-28789.r5">[5]</xref>
<xref ref-type="bibr" rid="article-28789.r6">[6]</xref>
</p>
        <p>Scopolamine can be used as an off-label adjunct to treat certain conditions listed below due to its anticholinergic properties.</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal spasms&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chemotherapy nausea</p>
          </list-item>
          <list-item>
            <p>Asthma attacks&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Smoking cessation therapy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Excessive sweating</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28789.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Scopolamine derives from the plants of <italic toggle="yes">Datura stramonium</italic> (Jimsonweed), <italic toggle="yes">Scopolia carniolica</italic>, and <italic toggle="yes">Hyoscyamus niger</italic> (henbane). These plants produce toxic compounds called belladonna alkaloids as a protective mechanism.<xref ref-type="bibr" rid="article-28789.r7">[7]</xref>&#x000a0;Scopolamine competitively inhibits G-protein coupled post-ganglionic muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects.<xref ref-type="bibr" rid="article-28789.r8">[8]</xref>&#x000a0;It is structurally very similar to atropine and is useful in conditions requiring decreased parasympathetic activity. Peripherally this results in smooth muscle relaxation and reduced gland secretion. Centrally, unlike atropine, scopolamine causes mostly sedation, but over-excitement and restlessness can occur at higher doses.<xref ref-type="bibr" rid="article-28789.r7">[7]</xref></p>
        <p>The vomiting center of the brain is located in the medulla oblongata and contains a high amount of M1 muscarinic acetylcholine, H1 histamine, NK1, and 5-HT3 serotonin receptors. Thus, any agent that antagonizes these receptors will have antiemetic properties. Scopolamine exerts its action by primarily affecting the M1 receptor. However, some research has reported H1 receptor activity.<xref ref-type="bibr" rid="article-28789.r7">[7]</xref></p>
      </sec>
      <sec id="article-28789.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The most commonly used dose form of scopolamine in the United States is a transdermal patch. Each patch is a circular shape of about 2.5 cm in diameter and 0.2 mm in thickness. Its design is in four layers for step-wise delivery of a priming dose of 140 micrograms of scopolamine initially, followed by a steady 1.5 mg release over 72 hours.<xref ref-type="bibr" rid="article-28789.r9">[9]</xref> The onset of action of scopolamine is four hours, and the peak effect of the patch occurs at 24 hours. Per package labeling, the recommendation is to apply scopolamine the night before surgery if used to prevent postoperative nausea and vomiting or four hours before exposure if used for motion sickness. For cesarean sections, apply one hour before surgery to limit exposure to the baby. The manufacturer also recommends discontinuation of the patch 24 hours after surgery because there was no significant antiemetic effect of scopolamine for PONV between 24 and 48 hours. For motion sickness, reapplication can be every 72 hours.<xref ref-type="bibr" rid="article-28789.r7">[7]</xref><xref ref-type="bibr" rid="article-28789.r10">[10]</xref><xref ref-type="bibr" rid="article-28789.r11">[11]</xref></p>
        <p>Patch placement should be on the postauricular area (the hairless area behind the&#x000a0;ear). The stratum corneum, which acts as a significant barrier to percutaneous absorption, is the thinnest at this location.&#x000a0;Patients should not cut the scopolamine patch, as it will alter the delivery system, and blood levels become less controlled.&#x000a0;There are two other scopolamine products available outside the USA: scopolamine hydrobromide and scopolamine butylbromide. Both are useable in parenteral, intramuscular, intravenous, and subcutaneous forms. The short duration of action, less predictable blood levels, and common side effects resulted in the exclusion of these products from U.S. markets.<xref ref-type="bibr" rid="article-28789.r9">[9]</xref></p>
      </sec>
      <sec id="article-28789.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most commonly reported side effects of scopolamine patch use are blurred vision, dilated pupils, and&#x000a0;dry mouth. The vision&#x000a0;disturbances are most often due to inadequate handwashing techniques after the application of the&#x000a0;patch.<xref ref-type="bibr" rid="article-28789.r1">[1]</xref> Less frequently reported side effects are related to anticholinergic toxidrome: flushed skin, tachycardia, agitation, and confusion. These side effects are usually mild and quick to resolve after patch removal. If needed, the clinician can administer a reversal agent like physostigmine if a side effect&#x000a0;persists.<xref ref-type="bibr" rid="article-28789.r8">[8]</xref><xref ref-type="bibr" rid="article-28789.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28789.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The FDA currently lists two contraindications for scopolamine: allergy to belladonna alkaloids and angle-closure glaucoma.&#x000a0;Patients with angle-closure glaucoma should not be prescribed scopolamine. Scopolamine causes mydriasis or pupillary dilation. A dilated iris prohibits proper drainage of fluid from the anterior chamber, creating a further increase in anterior chamber pressure and precipitating acute angle-closure glaucoma.<xref ref-type="bibr" rid="article-28789.r13">[13]</xref></p>
      </sec>
      <sec id="article-28789.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There are several conditions&#x000a0;in which scopolamine use requires caution or its effects monitored more frequently.</p>
        <p>There are reports of scopolamine worsening&#x000a0;psychosis. Reports also exist of acute toxic psychosis, agitation, speech disorder, hallucinations, paranoia, and delusions.<xref ref-type="bibr" rid="article-28789.r14">[14]</xref><xref ref-type="bibr" rid="article-28789.r15">[15]</xref>&#x000a0;Patients need monitoring for new or worsening psychiatric symptoms during treatment.</p>
        <p>Use caution in using&#x000a0;scopolamine for patients with myasthenia gravis. Myasthenia gravis is caused by a lack of proper nerve impulse transmission due to antibodies to acetylcholine receptors, resulting in muscle fatigue. Although myasthenia gravis primarily affects skeletal muscle, the use of anticholinergic agents, like scopolamine, causes unpredictable results.<xref ref-type="bibr" rid="article-28789.r16">[16]</xref></p>
        <p>There has been some concern about the use of scopolamine in patients with a seizure history. The speculated reason is that scopolamine might lower seizure threshold potential. However, further examination of medical records showed this not to be true. This false claim was primarily attributable to the coding of reported cases as "dizziness, rule out seizures." Patients in these cases did not experience an actual seizure or had it before the application of&#x000a0;scopolamine.<xref ref-type="bibr" rid="article-28789.r17">[17]</xref>&#x000a0;Nonetheless, there is a valid concern for seizure induction with the use of scopolamine in patients with severe preeclampsia. Currently, the understanding of preeclampsia has its basis in a vasospasm theory, and the use of anticholinergic agents may leave the sympathetic system unopposed, further deteriorating the condition of preeclampsia into eclampsia and HELLP&#x000a0;syndrome.<xref ref-type="bibr" rid="article-28789.r18">[18]</xref></p>
        <p>Patients should also discontinue using a scopolamine patch before MRI. One of the four layers contains metal and can burn the skin during MRI imaging.<xref ref-type="bibr" rid="article-28789.r7">[7]</xref></p>
        <p>Due to scopolamine's anticholinergic properties, its use can decrease gastrointestinal motility and cause urinary retention.<xref ref-type="bibr" rid="article-28789.r19">[19]</xref> In patients suspected of having intestinal obstruction, pyloric obstruction, urinary bladder neck obstruction, or patients receiving other anticholinergic drugs, consider more frequent monitoring during treatment. Discontinue scopolamine in patients who develop difficulty urinating.</p>
        <p>Scopolamine use also merits caution in special populations. Children, pregnant or lactating mothers, patients with hepatic or renal impairment, and the elderly should be monitored earlier for more severe side effects.</p>
        <p>There is no formal laboratory testing of&#x000a0;scopolamine levels currently available.</p>
      </sec>
      <sec id="article-28789.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity does not happen as frequently with the transdermal form of scopolamine due to its extended-release nature. Data on the toxic dose of scopolamine in the tablet form is scattered. Reports exist that 10 mg a day can be lethal for children. In adults, consumption of more than 100 mg a day did not result in death. The other feared toxidrome of scopolamine overdose is an anticholinergic syndrome resulting in tachycardia, hallucinations, hyperthermia, and dry membranes. Physostigmine 1 to 4 mg IV can&#x000a0;serve as an antidote in such severe cases. However, with the transdermal application, only minor side effects are most commonly&#x000a0;observed.<xref ref-type="bibr" rid="article-28789.r12">[12]</xref><xref ref-type="bibr" rid="article-28789.r9">[9]</xref></p>
      </sec>
      <sec id="article-28789.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Scopolamine is used extensively to prevent PONV in the hospital setting and motion sickness outside of the hospital, and its use and administration should have the involvement of an interprofessional team. Nursing staff should be knowledgeable about proper placement and side effects of scopolamine. The most commonly occurring are mucosal dryness and visual disturbances. The latter is usually due to touching the patch and rubbing the eyes or not properly washing hands after patch administration. Patch formulation prevents systemic toxicity, but one should be aware of the side effects of a possible overdose and monitor closely in specific populations. Nursing can monitor the patient's progress with therapy and check for adverse events in both inpatient and outpatient settings. Pharmacists should check for drug-drug interactions and educate patients and team members regarding the proper use and potential side effects. With an interprofessional team paradigm, scopolamine can achieve maximum therapeutic benefit with minimal adverse events. [Level 5]</p>
      </sec>
      <sec id="article-28789.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28789">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28789/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28789">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28789.s11">
        <title>References</title>
        <ref id="article-28789.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Kassel</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Scopolamine Use in the Perioperative Patient: A&#x000a0;Systematic Review.</article-title>
            <source>AORN J</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-295</page-range>
            <pub-id pub-id-type="pmid">30156728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brainard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gresham</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevention and treatment of motion sickness.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Jul</month>
            <day>01</day>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-6</page-range>
            <pub-id pub-id-type="pmid">25077501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>del Valle-Laisequilla</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Flores-Murrieta</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Granados-Soto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rocha-Gonz&#x000e1;lez</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Reyes-Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ketorolac tromethamine improves the analgesic effect of hyoscine butylbromide in patients with intense cramping pain from gastrointestinal or genitourinary origin.</article-title>
            <source>Arzneimittelforschung</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>603</fpage>
            <page-range>603-8</page-range>
            <pub-id pub-id-type="pmid">23093479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaire</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Subedi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A review on the pharmacological and toxicological aspects of Datura stramonium L.</article-title>
            <source>J Integr Med</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-9</page-range>
            <pub-id pub-id-type="pmid">23506688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>A Selective M<sub>1</sub> and M<sub>3</sub> Receptor Antagonist, Penehyclidine Hydrochloride, Exerts Antidepressant-Like Effect in Mice.</article-title>
            <source>Neurochem Res</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>2723</fpage>
            <page-range>2723-2732</page-range>
            <pub-id pub-id-type="pmid">31606838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlereth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dieterich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birklein</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hyperhidrosis--causes and treatment of enhanced sweating.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>106</volume>
            <issue>3</issue>
            <fpage>32</fpage>
            <page-range>32-7</page-range>
            <pub-id pub-id-type="pmid">19564960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pergolizzi</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raffa</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting.</article-title>
            <source>J Clin Anesth</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>334</fpage>
            <page-range>334-45</page-range>
            <pub-id pub-id-type="pmid">22608591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haronian</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hack</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Postoperative Anticholinergic Poisoning: Concealed Complications of a Commonly Used Medication.</article-title>
            <source>J Emerg Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>520</fpage>
            <page-range>520-523</page-range>
            <pub-id pub-id-type="pmid">28756934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renner</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kirch</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.</article-title>
            <source>Ther Drug Monit</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-65</page-range>
            <pub-id pub-id-type="pmid">16175141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ramesh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dalby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shestak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vallejo</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery.</article-title>
            <source>J Clin Anesth</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>249</fpage>
            <page-range>249-52</page-range>
            <pub-id pub-id-type="pmid">19502023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pergolizzi</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Raffa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of postoperative nausea and vomiting in adolescent patients: a review with emphasis on combination of fixed-dose ondansetron and transdermal scopolamine.</article-title>
            <source>J Drug Deliv</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>426813</fpage>
            <pub-id pub-id-type="pmid">21773046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corallo</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Whitfield</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic syndrome following an unintentional overdose of scopolamine.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>719</fpage>
            <page-range>719-23</page-range>
            <pub-id pub-id-type="pmid">19774213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamill</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Suelflow</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma.</article-title>
            <source>Ann Ophthalmol</source>
            <year>1983</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>1011</fpage>
            <page-range>1011-2</page-range>
            <pub-id pub-id-type="pmid">6651138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziskind</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Transdermal scopolamine-induced psychosis.</article-title>
            <source>Postgrad Med</source>
            <year>1988</year>
            <month>Sep</month>
            <day>01</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>73</fpage>
            <page-range>73-6</page-range>
            <pub-id pub-id-type="pmid">2901077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacEwan</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Remick</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Noone</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Psychosis due to transdermally administered scopolamine.</article-title>
            <source>CMAJ</source>
            <year>1985</year>
            <month>Sep</month>
            <day>01</day>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>431</fpage>
            <page-range>431-2</page-range>
            <pub-id pub-id-type="pmid">4027811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiess</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic agents for the treatment of "death rattle" in patients with myasthenia gravis.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>684</fpage>
            <page-range>684-6</page-range>
            <pub-id pub-id-type="pmid">12850651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strom</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schinnar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waiter</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-13</page-range>
            <pub-id pub-id-type="pmid">1855348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tokunaga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nishiguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanayama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Terao</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergics induce eclamptic seizures.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-4</page-range>
            <pub-id pub-id-type="pmid">12536341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28789.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dessie</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Hacker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Apostolis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boundy</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Modest</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rosenblatt</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Effect of Scopolamine Patch Use on Postoperative Voiding Function After Transobturator Slings.</article-title>
            <source>Female Pelvic Med Reconstr Surg</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-9</page-range>
            <pub-id pub-id-type="pmid">26825403</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
